FDA grants three priority vouchers to psychedelics
The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.
Newsletters and Deep Dive digital magazine
The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
The US Justice Department has issued an order moving medical marijuana to Schedule III, removing some barriers to access for patients and researchers.
Counterfeit drug promotion is a patient safety, brand equity, and public trust issue.
Editor's Picks
Newsletters and Deep Dive
digital magazine